Anemia Clinical Trial
Official title:
In Home Iron Fortification in Kenyan Infants: Effect of Co-supplementation With Galactooligosaccharides (GOS) on the Gut Microbiota Composition and the Effectiveness of Iron Supplementation
Iron deficiency and anemia are health issues affecting mainly infants and women in developing
countries. Iron deficiency in infancy can have long-lasting impact on cognitive and motor
development of the child. Iron fortification has shown to be effective against anemia.
However, in areas with a high burden of infectious diseases iron may increase the risk of
unfavorable gut microbiota composition possibly influencing diarrhea prevalence. Therefore we
want to assess the effects of home fortification of complementary food with two
iron-containing micronutrient powders (MNPs) with and without the addition of a prebiotic
(7.5 g of galactooligosaccharides as GOS-75) compared to a control on the composition of the
gut microbiota of Kenyan infants. In addition, iron deficiency may iimpair adaptive immunity.
Following Kenyan Minstry of Health guidelines, infants receive their first measles vaccine at
9 months. In this study we will use an MNP with a moderate iron dose of 5 mg, with 2.5 mg of
Fe as NaFeEDTA and 2.5 mg of Fe as ferrous fumarate (+Fe). There will be 3 study groups MNP,
MNP+Fe and MNP+Fe+GOS. The infants will be enrolled in the study at the age of 6-10 months
and will consume a home-fortified maize porridge for four months. At baseline and endpoint
(after 4 months of intervention), we will collect blood samples of the infants in order to
assess anemia, iron status, and inflammation. In addition, we will assess the effect of iron
supplementation on measles vaccine response. Fecal samples (from child and mother) will be
collected at baseline, 3 weeks and at endpoint in order to evaluate the changes in gut
microbiota and gut inflammation.
During the intervention, in a sub-group of children who receive broad-spectrum antibiotics,
we will compare how the three different interventions modify the effect of antibiotics on the
infant gut microbiota. We will opportunistically select children that are enrolled in the
study and who become ill, and who are prescribed antibiotics by the local health care team,
according to the local standard of care in the study area. Five additional stool samples from
these children will be collected (day 0 (before the first antibiotic dose), 5, 10, 20 and 40)
to evaluate the changes in the gut microbiota and gut inflammation.
Three years after the study end, we would like to collect a blood and stool sample from the
children and examine the iron status and gut microbiome respectively.
Fifty infants per group will be enrolled (n=150) and randomly divided in three groups, from
those identified in selected villages in the catchment area of the Kikoneni Health Clinic in
southern coastal Kenya, about 2 hours south of Mombasa. All children whose caregivers agree
to participate in the study will have their iron status assessed by measurement of hemoglobin
(Hb), erythrocyte zinc protoporphyrin (ZPP), serum ferritin (SF) and serum transferrin
receptor (TfR). Enrolled subjects will be randomized into three groups. Group 1 will receive
the MNP alone, group 2 will receive an identical MNP with iron (2.5 mg Fe as NaFeEDTA and 2.5
mg as ferrous fumarate), and group 3 will receive the MNP with iron (2.5 mg Fe as NaFeEDTA
and 2.5 mg as ferrous fumarate) and 7.5 mg of galactooligosaccharides as GOS-75. Each
household will receive 2 kg of maize meal per week and the caregivers of the participating
children will be shown how to prepare a maize porridge, which is the most widely-used local
complementary food. This maize meal will be provided free-of-charge to all participating
families. The caregiver will add one MNP sachet each day to a portion of maize porridge, and
feed the entire portion to the infant. The Kikoneni Clinic will serve as the collection point
for the MNPs, the monitoring center for surveillance of infant health, as well as the blood
and stool collection point.
At baseline and at endpoint of the intervention (after 4 months), a blood sample will be
collected from the infants for measurement of Hb, SF, TfR and ZPP to define anemia and iron
status and C-reactive protein (CRP) to define systemic inflammation status. In addition,
anti-measles Serum IgG will be measured, as infants receive their first measles vaccination
at 9 months, following Kenyan Ministry of Health guidelines. At baseline, after 3 weeks and
after 4 month, a stool sample will be collected from both the infant and his/her mother, for
measurement of the gut microbiota and gut inflammation.The mothers will be trained to collect
the stool samples at home in a provided container with a tight, screw-top lid, that includes
an Anerocult® sachet to create an anaerobic environment. At these 3 timepoints (baseline,
after 3 weeks and after 4 month) the mother will bring in the two stool samples of the same
day, where they will be labeled and kept at 4°C. The samples will be then transferred to the
central lab, filled in 2 ml Eppendorf tubes, labelled and frozen at -20°C.
In addition, compliance and morbidity will be assessed weekly during the distribution of the
MNPs. The children will be checked and referred to the health center clinicians whenever
indicated by the clinical history. In the case of fever, a rapid malaria test (RTD) kit will
be performed according to local guidelines. If the test results positive, the child will be
treated for presumptive malaria, mild malaria cases will be treated at Kikoneni clinic as per
WHO Integrated management of childhood illness (IMCI) guidelines. Cases of diarrhea will be
treated according to the local standard of care including oral rehydration salt and, if
necessary, antibiotics. If deemed necessary by the Kikoneni clinical management, the study
team will support the clinic in re stocking ORS, iron supplements and antimalaric drugs for
the study duration.
Anthropometry (weight, height, age and sex) will be recorded at baseline and endpoint using
standardized procedures to calculate the prevalence of child stunting. The measurements will
be done twice and the average used for data analysis. The data analysis software WHO Anthro
(WHO, Geneva Switzerland) will be used to calculate the prevalence of stunting among this
infant population.
To investigate the effect of oral antibiotics on the infant gut microbiota we will select the
first 12 infants of each of the three study groups that become ill during the study and
receive broad-spectrum antibiotic treatment. We will also select 6 non-treated controls from
each study group matched for sex and weeks of MNP consumption. A total of n=54 children will
be included in this sub study and we will collect five additional stool samples from the
selected children to determine the gut microbiota composition. The first stool sample will be
collected before starting the antibiotic treatment (day 0). Thereafter, a stool sample will
be collected at day 5, 10, 20 and 40. Stool samples will be collected as described above.
Besides these additional stool samples the children continue the intervention according to
the main protocol.
A breast milk sample will be collected from 90 mothers at two time points (week 3 and week
16). These samples will be analyzed for the concentration of human milk oligosaccharides, a
potential source of natural prebiotics.
Three years after the end of the study, we would like to examine iron status and gut
microbiota of these children and determine whether the differences observed after the
intervention persist or if they all converge and have a similar microbiome profile. In
addition, we will measure anti-measles serum IgG, as infants received their second measles
vaccine at 18 months following Kenyan Ministry of Health guidelines.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 |